Using wearable and mobile data to diagnose and monitor movement disorders
The goal of the study is to use data from a smartphone to differentiate diseases and measure symptom severity.
ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT04231487
About the Study
Eligible Ataxia Types
Spinocerebellar Ataxias
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
11/01/2018
Estimated Completion Date
11/01/2023
IRB Approval #
Pro2018002015
Location(s)
Rutgers University
65 Bergen Street
Newark, NJ
Contact Information
Jean-Francois Daneault
jf.daneault@rutgers.edu
Phone: 973-972-8482
What does participation in the study entail?
Participation entails coming to the laboratory located in Newark NJ, for one session lasting about 1 hour. Some people may be asked to use the smartphone app at home, once a week, for 8 weeks.
What are the potential benefits for participants?
Participants will not benefit directly from the study. They will help us develop a tool that may become available to individuals with ataxia to improve their diagnosis and long-term management.
What are the potential risks for participants?
The risks are no greater than doing regular activities during daily life, such as walking.
Is there financial compensation?
Yes. $40.
Is there travel reimbursement?
No.
Who is eligible?
Adults with a diagnosis of spinocerebellar ataxia and that have been on a stable dose of medication for at least 30 days are eligible. People with severe cognitive impairment that limit their understanding of simple instructions, that have a diagnosis of another neurological condition, and that have severe mobility impairments due to other conditions, such as arthritis, are not eligible.
View Other Research Opportunities
DRPLA Natural History and Biomarkers Study
This study aims to recruit paediatric and adult DRPLA mutation carriers and healthy controls across different countries. It aims to characterize the natural history of DRPLA in both juvenile- and Read More…
Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
The purpose of this study is to test the safety of the study drug, which is an adeno-associated virus serotype rh10 gene transfer vector (AAVrh.10hFXN), and see what effects it Read More…
Using MRI neurofeedback to enhance motor function in ataxia
The purpose of this study is to use a form of brain imaging (real-time functional magnetic resonance imaging, rt-fMRI) combined with neurofeedback, to train people with cerebellar ataxia to improve Read More…
